Novartis’ Ilaris unexpectedly slashes need for joint replacements from osteoarthritis in key study

Novartis has been laboring for the last few years to expand the market for Ilaris, a drug that’s currently approved to treat a few rare inflammatory diseases, but those efforts have turned in mixed results, particularly in cardiovascular disease.

Now Novartis has evidence that Ilaris might find a role in an unexpected therapeutic setting: osteoarthritis.